Paradigm Health

Paradigm Health is a technology company that builds infrastructure intended to make clinical trials part of routine patient care. Its platform is implemented directly at healthcare provider organizations and connects patients, providers, researchers and study sponsors through a single research infrastructure, with AI used to automate patient matching and site feasibility assessment. The stated mission is equitable access to trials for any patient, anywhere, by reducing barriers to participation for providers and improving trial efficiency for sponsors.

The company's primary focus is oncology: it supports Phase I–III oncology trials for 15 of the top 20 global pharmaceutical companies and, following its acquisition of Flatiron Health's Clinical Research Business, describes itself as operating the largest oncology research network in the United States. It is extending its commercial business into neuroscience, cardiovascular disease, metabolic conditions and other therapeutic areas. In addition to platform software, Paradigm offers services across the trial journey, including a recently launched Trial Design Service that helps sponsors design and execute interventional and pragmatic trials embedded in routine care.

Paradigm was incubated in 2021 by ARCH Venture Partners (co-incubated with General Catalyst per one account) to address inequities in patient access to clinical research, and is backed by healthcare and life sciences investors. It is headquartered at 175 S. 3rd St, Suite 1000, Columbus, Ohio, with a New York presence noted in funding announcements.

Founding story

The company was conceived and incubated by ARCH Venture Partners in 2021 to address inequities in patient access to clinical research; one account states it was co-incubated by ARCH and General Catalyst. Robert Nelsen of ARCH is described as Co-Founder and Board Chair, and Kent Thoelke, a 30-year clinical research industry veteran and former Chief Innovation Officer at ICON plc and Chief Scientific Officer at PRA Health Sciences, is founder and CEO [2][4][6].

Business model

Paradigm combines software with services, integrating its research infrastructure into health provider organizations and serving two customer sides: biopharmaceutical sponsors who need trials run faster and at lower cost, and provider organizations that want to offer trials locally. Product lines described include sponsor-facing and provider-facing offerings plus a Trial Design Service for interventional and pragmatic trials [0][4][5].

Sources describe a commercial business serving biopharma sponsors and health systems and a Trial Design Service sold to sponsors, but do not disclose pricing, contract structure or revenue figures [4][5][6].

Traction

Reported metrics include coverage of 45 U.S. states, 166 provider organizations, 2,100 care locations, 123 community oncology practices, 43 health systems and academic medical centers (23 NCI-Designated Cancer Centers), 70% of the U.S. cancer population within easy access to a site, support for 15 of the top 20 global pharma companies, and four-times-faster trial accrual. Customer case studies cite a 45% increase in clinical trial participation at Highlands Oncology over two years and a 41% increase in patient screening capacity at Ochsner Health [0][2][4][5][7].

Latest developments

December 2025: oversubscribed $78 million Series B led by ARCH Venture Partners with new investor DFJ Growth and existing investors, announced together with the acquisition of Flatiron Health's Clinical Research Business and a multi-year cross-integration partnership with Flatiron (including embedding Paradigm tools in OncoEMR). The company also recently launched a Trial Design Service. Later company news items list a June 2026 submission to the FDA's Real-Time Clinical Trials Initiative RFI and an August 2026 expansion with Ochsner Health across the Gulf South [2][4][5][6].